The pivotal role of IL-6 in mediating the acute phase response seems to interest the strategical treatment in COVID-19 patients. Researches are still in progress and it would be intriguing to investigate whether people with obesity and higher circulating IL-6 levels, compared with lean controls, respond more favourably to IL-6 inhibition strategies in SARS-CoV-2 pandemic [43].